New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19-Reference-Cited by-同舟云学术

New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19

Published:2020-12-16 Issue:1 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Aleissa Muneerah M.¹,Silverman Emily A.²,Paredes Acosta Luisa M.³⁴,Nutt Cameron T.³⁴,Richterman Aaron⁵,Marty Francisco M.²³⁴^ORCID

Affiliation:

1. Department of Pharmacy, Brigham and Women’s Hospital, Boston, Massachusetts, USA

2. Division of Infectious Diseases, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA

3. Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA

4. Harvard Medical School, Boston, Massachusetts, USA

5. Division of Infectious Diseases, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

Abstract

Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19). Remdesivir is the prodrug of an adenosine analogue that inhibits viral replication of several RNA virus families, including Coronaviridae . Preclinical data in animal models of coronavirus diseases, including COVID-19, have demonstrated that early treatment with remdesivir leads to improved survival, decreased lung injury, and decreased levels of viral RNA.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01814-20

Reference60 articles.

1. A Review of SARS-CoV-2 and the Ongoing Clinical Trials

2. SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat

3. A pneumonia outbreak associated with a new coronavirus of probable bat origin

4. The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control

5. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world Efficacy of Ensitrelvir in Hospitalized Patients with COVID-19 in Japan: A Retrospective Observational Study;2024-02-06

2. Use of Real-World EMR Data to Rapidly Evaluate Treatment Effects of Existing Drugs for Emerging Infectious Diseases: Remdesivir for COVID-19 Treatment as an Example;Statistics in Biosciences;2024-01-02

3. Pulmonary delivery of remdesivir and dexamethasone encapsulated nanostructured lipid carriers for enhanced inflammatory suppression in lung;Journal of Drug Delivery Science and Technology;2023-12

4. COVID-19: Impact, Diagnosis, Management and Phytoremediation;Current Traditional Medicine;2023-12

5. Inhibition of SARS-CoV-2 3CL protease by the anti-viral chimeric protein RetroMAD1;Scientific Reports;2023-11-17